This study examines whether tumour size can be described using patient age, number of lymph node metastases, Ki67 index, Estrogen Receptor (ER)/Progesterone Receptor (PR)/Human Epidermal Growth Factor Receptor 2 (HER2) status, tumour type, and molecular subtype in Early Breast Cancer (EBC) patients with clinically negative Axillary Lymph Nodes.

